Inhibition of Nogo: a key strategy to increase regeneration, plasticity and functional recovery of the lesioned central nervous system.
In the adult central nervous system (CNS) myelin and oligodendrocytes, Nogo-A exerts a growth inhibitory function leading to restricted axonal regeneration. After development of different anti-Nogo-A antibodies and other Nogo-A blocking reagents their application has recently been studied in various in vivo animal models of spinal cord injury and stroke. These studies show that intracerebral application of Nogo-A-inactivating reagents leads to enhanced regeneration and compensatory sprouting, structural reorganization or plasticity, and functional recovery as seen in different behavioural analyses.
Buchli
Anita D
AD
Brain Research Institute, University of Zurich and Department of Biology, Swiss Federal Institute of Technology-Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
Schwab
Martin E
ME
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001369:Axons / Q000502:physiology*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D006131:Growth Inhibitors / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D006801:Humans; D009185:Myelin Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D009416:Nerve Regeneration / Q000502:physiology*; D009473:Neuronal Plasticity / Q000502:physiology*; D000070798:Nogo Proteins; D020127:Recovery of Function / Q000502:physiology*; D029867:Xenopus Proteins / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D006131:Growth Inhibitors; D009185:Myelin Proteins; D000070798:Nogo Proteins; C000603199:RTN4 protein, human; D029867:Xenopus Proteins